Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Bicycle Therapeutics plc, 3 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 4, 2026 | Danaher Corporation | Grant or award | +13,477 | — | — |
| Mar 1, 2026 | Danaher Corporation | Grant or award | +6,647 | — | — |
| Mar 1, 2026 | Danaher Corporation | Shares withheld for tax | −284 | $210.64 | $59,822 |
| Feb 24, 2026 | Danaher Corporation | Shares withheld for tax | −344 | $209.19 | $71,961 |
| Feb 4, 2026 | Danaher Corporation | Grant or award | +1,695 | — | — |
| Feb 2, 2026 | Danaher Corporation | Shares withheld for tax | −852 | $223.42 | $190,354 |
| Jan 2, 2026 | Bicycle Therapeutics plc | Grant or award | +9,500 | — | — |
| Mar 1, 2025 | Danaher Corporation | Shares withheld for tax | −216 | $207.76 | $44,876 |
| Feb 24, 2025 | Danaher Corporation | Shares withheld for tax | −586 | $211.14 | $123,728 |
| Jan 2, 2025 | Bicycle Therapeutics plc | Grant or award | +6,250 | — | — |
| Mar 1, 2024 | Danaher Corporation | Grant or award | +2,932 | — | — |
| Feb 26, 2024 | Danaher Corporation | Shares withheld for tax | −866 | $253.84 | $219,825 |
| Feb 21, 2024 | Danaher Corporation | Grant or award | +3,155 | — | — |
| Jan 2, 2024 | Bicycle Therapeutics plc | Grant or award | +6,000 | — | — |
| Aug 21, 2023 | Danaher Corporation | Open-market sale | −590 | $250.54 | $147,819 |
Questions about Jose-Carlos Gutierrez-Ramos
What boards is Jose-Carlos Gutierrez-Ramos on?
Jose-Carlos Gutierrez-Ramos sits on the board of Bicycle Therapeutics plc.
How long has Jose-Carlos Gutierrez-Ramos served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.